Related Experiment Video
Updated: Jul 20, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Rational selection of an ideal oncolytic virus to address current limitations in clinical translation
1Humane Genomics, New York, NY, United States.
Abstract:
Oncolytic virus therapy (OVT) is a promising modality that leverages the propensity of natural or engineered viruses to selectively replicate in and kill cancer cells. Over the past decade, (pre)clinical studies have focused on the development and testing of adenovirus, herpes simplex virus, and vaccinia virus-based vectors. These studies have identified barriers to success confronting the field. Here, we propose a set of selection criteria or ideal properties of a successful oncolytic virus, which include lack of pathogenicity, low seroprevalence, selectivity (infection and replication), transgene carrying capacity, and genome stability. We use these requirements to analyze the oncolytic virus landscape, and then identify a potentially optimal species for platform development - vesicular stomatitis virus.
Insights
Oncolytic virus therapy (OVT) uses viruses to kill cancer cells. Researchers identified ideal virus properties and suggest vesicular stomatitis virus as a promising platform for OVT development.
Area of Science:
- Oncology
- Virology
- Biotechnology
Background:
- Oncolytic virus therapy (OVT) shows promise for cancer treatment by utilizing viruses that selectively infect and destroy cancer cells.
- Current research has focused on adenovirus, herpes simplex virus, and vaccinia virus vectors, revealing significant challenges in the field.
- Barriers to successful OVT include pathogenicity, high seroprevalence, and insufficient selectivity, replication, or stability.
Purpose of the Study:
- To define ideal properties for an oncolytic virus platform.
- To evaluate existing oncolytic viruses against these criteria.
- To identify a superior candidate for future OVT development.
Main Methods:
- Defined key selection criteria for oncolytic viruses: non-pathogenicity, low pre-existing immunity (seroprevalence), selective tumor infection and replication, transgene capacity, and genomic stability.
- Assessed the landscape of potential oncolytic viruses based on these criteria.
- Identified vesicular stomatitis virus as a promising candidate.
Main Results:
- Established a framework for evaluating oncolytic virus candidates.
- Highlighted limitations of currently studied viruses like adenovirus, HSV, and vaccinia.
- Vesicular stomatitis virus emerged as a strong contender due to its favorable characteristics.
Conclusions:
- The proposed criteria provide a roadmap for developing effective oncolytic viruses.
- Vesicular stomatitis virus possesses a unique combination of properties making it an optimal choice for further platform development in oncolytic virus therapy.
- Further research into vesicular stomatitis virus-based OVT is warranted.
